

? ds

Set Items Description

S1 53 HEMOLYSIN AND (FUNGUS OR FUNGAL OR STACHYBOTRYS OR CANDIDA

OR ASPERGILLUS OR PENICILLIUM) AND ANTIBOD?

S2 35 RD S1 (unique items)

S3 29 HEMOLYSIN AND (ALBICANS OR CHARTARUM OR FUMIGATUS OR CHRYS-

OGENUM) AND ANTIBOD?

S4 11 S3 NOT S2

S5 5 RD S4 (unique items)
S6 307 HEMOLYSIN AND (ALBICANS OR CHARTARUM OR FUMIGATUS OR
CHRYS-
OGENUM)

S7 112 RD S6 (unique items)

S8 96 S7 NOT (S2 OR S3)

? logoff y

09jun03 09:27:22 User226352 Session D705.3

\$1.91 0.341 DialUnits File5

\$43.75 25 Type(s) in Format 7

\$43.75 25 Types

\$45.66 Estimated cost File5

\$0.33 0.056 DialUnits File6

\$3.80 2 Type(s) in Format 7

\$3.80 2 Types

\$4.13 Estimated cost File6

\$5.43 0.293 DialUnits File34

\$5.35 1 Type(s) in Format 2

\$112.35 21 Type(s) in Format 7

\$117.70 22 Types

\$123.13 Estimated cost File34

\$0.31 0.044 DialUnits File40

\$0.31 Estimated cost File40

\$1.93 0.428 DialUnits File50

\$46.00 23 Type(s) in Format 7

\$46.00 23 Types

\$47.93 Estimated cost File50

\$0.18 0.048 DialUnits File65

\$0.18 Estimated cost File65

\$1.47 0.195 DialUnits File71

\$1.68 1 Type(s) in Format 7

\$1.68 1 Types

\$3.15 Estimated cost File71

\$3.62 0.392 DialUnits File73

\$17.85 7 Type(s) in Format 7

\$17.85 7 Types

\$21.47 Estimated cost File73

?s10/2001

87 S10

285421 PY=2001

S12 2 S10/2001

?s10 not s12

87 S10

2 S12

S13 85 S10 NOT S12

?s s13 and (antibod? or monoclonal? or polyclonal? or antiser? or immunoglob? or elisa or eliza or eia or eifla or assay?)

85 S13

571115 ANTIBOD?

153903 MONOCLONAL?

31604 POLYCLONAL?

51815 ANTISER?

117627 IMMUNOGLOB?

40980 ELISA

40 ELIZA

4925 EIA

0 EIFLA

377827 ASSAY?

S14 21 S13 AND (ANTIBOD? OR MONOCLONAL? OR POLYCLONAL? OR

ANTISER? OR IMMUNOGLOB? OR ELISA OR

ELIZA OR EIA OR EIFLA

OR ASSAY?)

?t s14/9/all

14/9/1

DIALOG(R)File 155:MEDLINE(R)

10773135 20095921 PMID: 10632060

The comparison of characteristics between membrane-active antifungal peptide and its pseudopeptides.

Oh JE; Hong SY; Lee KH

Protein Chemistry Laboratory, Mogam Biotechnology Research Institute,

Yongin-city, Kyunggi-Do, South Korea.

Bioorganic & medicinal chemistry (ENGLAND) Nov 1999, 7 (11) p2509-15

, ISSN 0968-0896 Journal Code: B38

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Subfile: INDEX MEDICUS

By the introduction of various amide surrogates, novel pseudopeptides

corresponding to a membrane active depsi-peptide were synthesized and their

native characteristics compared with that of the peptide. The pseudopeptides had more resistance to serum proteases than the peptide and

similar antimicrobial activities to that of the peptide without hemolytic

activity. The pseudopeptides like the peptide were active against current

drug resistant fungi and pathogenic fungi isolated from patients, and also

had a strong synergism with current antifungal drugs against Candida

albicans. The leakage assay suggested that the pseudopeptides also acted

on the lipid membrane of pathogenic cells. These results indicated that the

novel pseudopeptides had advantages over the peptide as a candidate for a

novel antifungal drug and backbone modifications can be a tool in the

development of a novel antifungal agent from membrane-active peptides

isolated from natural sources or chemically synthesized.

Tags: Support, Non-U.S. Gov't

Descriptors: Antifungal Agents--pharmacology--PD; *Candida albicans

--drug effects--DE; *Oligopeptides--pharmacology--PD; Antifungal Agents

--chemistry--CH; Circular Dichroism; Drug Synergism; Half-Life; Hemolysis

--drug effects--DE; Liposomes; Microbial Sensitivity Tests

CAS Registry No.: 0 (Antifungal Agents); 0 (Liposomes); 0

(Oligopeptides); 0

(lysyl-lysyl-valyl-valyl--phenylalanyl-lysyl-valyl-lysyl-phenylalanyl-lysyl-lysineamide); 0

(lysyl-lysyl-valyl-valyl-phenylalanyl-lysyl-lysine)

-lysyl-valyl-lysyl-phenylalanyl-lysine)

Record Date Created: 20000214

14/9/2

DIALOG(R)File 155:MEDLINE(R)

10149127 99268435 PMID: 10338113

A critical comparison of the hemolytic and fungicidal activities of cationic antimicrobial peptides.

Helmerhorst EJ; Reijnders IM; van 't Hof W; Veerman EC; Nieuw Amerongen

AV

Academic Centre for Dentistry Amsterdam (ACTA),

Department of Oral

Biochemistry, Vrije Universiteit, The Netherlands.

ej.helmerhorst.obc.acta@

med.vu.nl

FEBS letters (NETHERLANDS) Apr 23 1999, 449 (2-3)

p105-10, ISSN

0014-5793 Journal Code: EUH

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Subfile: INDEX MEDICUS

The hemolytic and fungicidal activity of a number of cationic antimicrobial peptides was investigated. Histatins and magainins were

inactive against human erythrocytes and Candida albicans cells in phosphate

buffered saline, but displayed strong activity against both cell types when

tested in 1 mM potassium phosphate buffer supplemented with 287 mM glucose.

The HC50/IC50 ratio, indicative of the therapeutic index, was about 30 for

all peptides tested. PGLa was most hemolytic (HC50 = 0.6 microM) and had

the lowest therapeutic index (HC50/IC50 = 0.5). Susceptibility to

hemolysis was shown to increase with storage duration of the erythrocytes

and also significant differences were found between blood collected from

different individuals. In this report, a sensitive assay is proposed for the testing of the hemolytic activities of cationic peptides. This assay

detects subtle differences between peptides and allows the comparison

between the hemolytic and fungicidal potency of cationic peptides.

Tags: Animal; Comparative Study; Human; Support, Non-U.S. Gov't

Descriptors: Antifungal Agents--pharmacology--PD; *

Hemolysis

--pharmacology--PD; *Peptides--pharmacology--PD; *Salivary

Proteins

--pharmacology--PD; Amino Acid Sequence; Candida albicans